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Anthelmintic resistance is widespread in gastrointestinal nematode populations, such that there is a
consistent need to search for new anthelmintics. However, the cost of screening for new compounds is
high and has a very low success rate. Using the knowledge of traditional healers from Borneo Rainforests
(Sarawak, Malaysia), we have previously shown that some traditional medicinal plants are a rich source
of potential new anthelmintic drug candidates. In this study, Picria fel-terrae Lour. plant extract, which
has previously shown promising anthelmintic activities, was fractionated via the use of a solid phase
extraction cartridge and each isolated fraction was then tested on free-living nematode Caenorhabditis
elegans and the parasitic nematode Haemonchus contortus. We found that a single fraction was enriched
for nematocidal activity, killing 90% of C. elegans adults and inhibiting the motility of exsheathed L3 of
H. contortus, while having minimal cytotoxic activity in mammalian cell culture. Metabolic proﬁling and
chemometric analysis of the effective fraction indicated medium chained fatty acids and phenolic acids
were highly represented.
Crown Copyright © 2016 Published by Elsevier Ltd on behalf of Australian Society for Parasitology. This is
an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.
0/).1. Introduction
Gastrointestinal nematode infections of ruminants remain a
major threat to the economic viability of the livestock industry
(Nieuwhof and Bishop, 2005; Sackett et al., 2006). The control of
these parasitic diseases depends on the use of commercial
anthelmintic drugs (Molento et al., 2011), together with manage-
ment practices (Kahn and Woodgate, 2012; Miller and Waller,m Cells Program, Monash
Biochemistry and Molecular
0, Australia.
).
vier Ltd on behalf of Australian So2004; Van wyk et al., 2006, Waller, 1993; Woodgate and Besier,
2010). However, resistance to anthelmintics is widespread in hel-
minth populations (Fleming et al., 2006); therefore, there is a
continuous need for the development of novel anthelmintic drugs.
The cost of developing new anthelmintic compounds is high, and
very few new compounds have been discovered or synthesized in
the last decade (Csermely et al., 2013; Mackenzie and Geary, 2013).
This is augmented by the fact that nations that suffer most from
helminth infections are countries with limited resources to invest
in drug discovery research and, as such, are also ﬁnancially unat-
tractive to the global pharmaceutical industry (Brooker, 2010).
In the last decade, there has been renewed interest in phyto-
medicine, and many traditional medicinal plants species are beingciety for Parasitology. This is an open access article under the CC BY-NC-ND license
R. Kumarasingha et al. / International Journal for Parasitology: Drugs and Drug Resistance 6 (2016) 171e178172tested for pharmacological activities (Agyare et al., 2009; Aremu
et al., 2010; Desrivot et al., 2007; Katiki et al., 2011, Ndjonka et al.,
2011, Waterman et al., 2010). Although plant-based remedies
have been used for centuries in traditional medicine for the treat-
ment of various diseases, includingworm infections, there has been
limited scientiﬁc evaluations of their actual activities, properties
and toxicities (Eguale et al., 2011; Kaewintajuk et al., 2010; Ndjonka
et al., 2011; Heckendorn et al., 2007; Molan et al., 2003).
Previously, we have shown that traditional medicinal plants are
a rich source of anthelmintic drug candidates (Kumarasingha et al.,
2014). Plant extracts were selected based on the knowledge of
traditional healers from Borneo Rainforests, Sarawak, Malaysia, and
screened for anthelmintic compounds in Caenorhabditis elegans
(Kumarasingha et al., 2014). The present study reports the frac-
tionation of the most active plant extract, derived from the whole
plant of Picria fel-terrae Lour., and identiﬁcation of a single fraction
(designated Fraction 5) that is enriched for anthelmintic activity.
P. fel-terrae Lour. is a popular medicinal plant in Asia, and has been
studied for its anti-microbial and anti-inﬂammatory activities
(Ahmed and Halaweish, 2014; Huang et al., 1998, 1999; Zou et al.,
2006). To the best of our knowledge, apart from our previous
work, testing of the anthelmintic activity of this plant has not been
reported in the literature.
2. Materials and methods
2.1. Preparation of plant extracts
Plant extracts were prepared at the Sarawak Biodiversity Centre,
Kuching, Malaysia. Whole P. fel-terrae Lour. Plants were dried,
ground into a powder, extracted into 1:1 v/v dichlor-
omethane:methanol and then concentrated using a rotary evapo-
rator. Before use, the powdered plant extracts were dissolved in
absolute ethanol (Merck, Australia) and diluted in M9 buffer
(85.6 mMNaCl, 4.2 mMNa2HPO4, 2.2 mMKH2PO4,1 mMMgSO4) to
achieve the desired concentration (Brenner, 1974). The ﬁnal ethanol
concentration of all dilutions was 1% (v/v).
2.2. Fractionation of P. fel-terrae Lour. whole plant extract
A solid phase extraction (SPE) strata C18-E cartridge (Silica-
based sorbent; Phenomenex, USA) was used for sample fraction-
ation. Plant extract (100mg) was dissolved in 1 ml absolute ethanol
and diluted with 19 ml MilliQ water. The column was washed with
20 ml of 100% Acetonitrile (ACN; Sigma, Australia) and then 20 ml
of MilliQ water was sent through to condition the column. The
dissolved plant extract was loaded on the column and eluted by
passing 20 ml of 10%, 25%, 40%, 55%, 70%, 85% and 100% ACN
dilution series. The fractions obtained were dried by rotary evap-
oration. Individual fractions were solubilised in 1 ml of absolute
ethanol and 10 ml aliquots were added to 990 ml of M9 to make
working solutions.
2.3. C. elegans strains and maintenance
C. elegans “Bristol N2” wild type strain was used for all the ex-
periments. All the strains were grown on Nematode Growth Me-
dium (NGM) in petri dishes containing a lawn of Escherichia coli
OP50 (Brenner, 1974). Strains were grown at 20 C and synchron-
ised populations were obtained by a modiﬁed alkaline bleaching
method (Lenaerts et al., 2008). Brieﬂy, worm culture plates with
eggs and egg-laying adults were washed in M9 and then incubated
in a freshly prepared bleaching solution (4 ml commercial bleach,
1 ml 1 M NaOH and 9 ml H2O) for 3.5 min, followed by washing 3
times with M9. Eggs in M9 were kept on a rotaty shaker at 20 Covernight to hatch. First stage larvae (L1s) were put on to NGM
plates the next morning and incubated at 20 C. Young adults were
isolated 48 h later. These worms were washed 4 times in M9 before
being used in experiments.2.4. Efﬁcacy of fractions of P. fel-terrae Lour. Whole-plant extracts
on C. elegans adults
The 9 fractions collected following SPE fractionationwere tested
on C. elegans young adults. Assays were performed in 96-well
microtitre plates using 150 ml media per well, with 3 replicates
per condition (10 worms per well) as described previously
(Kumarasingha et al., 2014). The plates were covered and kept in a
humid chamber on a shaker at 20 C, and survivors were counted at
speciﬁc time points for up to 72 h. Worms were considered dead if
they were immobile, even after provocation with a platinum wire,
and if no pharyngeal pumping was detected. Two conventional
anthelmintic drugs, doramectin (Pﬁzer, Australia) and levamisole
(Sigma, Australia) were used as positive controls, and M9 with 1%
ethanol was used as a negative control. Each condition was per-
formed in triplicate, and three biological repeats were performed
for each experiment.2.5. Production and storage of H. contortus third-stage larvae (L3s)
Haemonchus contortus (Haecon-5 strain; cf. Schwarz et al., 2013)
was maintained in experimental sheep as described previously
(Preston et al., 2015) and in accordance with the institutional ani-
mal ethics guidelines (permit no. 1111938; The University of Mel-
bourne). To produce L3s, faecal samples were incubated at 27 C for
7e10 days before larvaewere harvested (cf. Schwarz et al., 2013). L3
were stored at 10 C for up to three months prior to use.2.6. Exsheathment of L3s
L3s were exsheathed and sterilised by incubation in 0.15% (v/v)
sodium hypochlorite (NaClO) at 37 C for 20 min as described by
Preston et al. (2015). Following exsheathment, L3s (designated
xL3s) were suspended at a density of 300 xL3 in 50 ml of Luria
Bertani medium (LB) supplemented with 100 IU/ml of penicillin,
100 mg/ml of streptomycin and 2.5 mg/ml of amphotericin (Fungi-
zone®,Thermo Fisher Scientiﬁc, Australia; designated LB*).2.7. H. contortus exsheathed third stage larvae (xL3) motility assay
To test for activity, the test fractions (0.01 mg/ml) and the sol-
vent control in LB* with 1% ethanol were arrayed in triplicate in 96
well ﬂat-bottomed plates (Corning, 3650, Life Sciences, USA). Six
wells were used for the negative control (LB* þ 1% ethanol); 300
L3s were dispensed (in 50 ml) into the wells using a multi-channel
pipette and amini-air pump (Air-pump-S100; Aquatrade, Australia)
to keep the parasites suspended, as described by Preston et al.
(2015). The perimeter wells were ﬁlled with 200 ml of sterile wa-
ter. Plates were incubated at 38 C and 10% CO2 (v/v). Following a
48 h incubation period, the motility of the xL3s was assessed as
described previously (Preston et al., 2015). In brief, the plates were
agitated on an orbital shaker for 30min at 38 C prior to recording a
10 s video of each well using an eyepiece camera (Dino-eye, ANMO
Electronic Corporation, Taiwan) attached to a stereo dissecting
microscope (Olympus, Japan). Each video was then processed for
motility by calculating the changes in pixel intensity using a custom
macro in the program ImageJ (1.47v, imagei.nih.gov/ij), as described
in detail by Preston et al. (2015).
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the effective fraction
Replicate freeze-dried samples (n ¼ 5) of each fraction
(50 ± 2 mg) were prepared for derivatization as previously
described (Karpe et al., 2015b; Ng et al., 2012). The stored samples
were volatilized by derivatization for application in Gas
Chromatography-Mass Spectrometry (GC-MS). Methoxymine HCl
(40 ml, 2% w/v in pyridine) was added to the samples, followed by
vortexing at 37 C in a thermomixer (Eppendorf, Australia) at
1400 rpm for 45 min. Silylation was performed by adding 70 ml of
N,O-Bis(trimethylsilyl)triﬂuoroacetamide (BSTFA) in 1% Trimethyl-
chlorosilane (TMCS) to complete the derivatization. The mixture
was then centrifuged at 15,700  g for 5 min and the supernatant
was transferred to GC-MS vials. Pre-derivatized 13C-Sorbitol
(Kovats Retention Index ¼ 1918.76, m/z ¼ 620.00 [10 mg/ml, HPLC
grade, Sigma-Aldrich, Australia]) was added as the second internal
standard at this point in order to verify instrument stability over
the run time.
The derivatized samples were analysed using an Agilent 6890B
Gas Chromatograph oven coupled to a 5973A Mass spectrometer
detector (Agilent Technologies, Australia), as described previously
(Beale et al., 2013, 2014). The GC-MS systemwas ﬁtted with a 30 m
DB-5MS column, 0.25 mm ID and 0.25 mm ﬁlm thickness. All in-
jections were performed at 1:10 split mode with 1.0 ml volume; the
oven was held at an initial temperature of 70 C for 2 min before
increasing to 325 C at 7.5 Cmin1; the ﬁnal temperaturewas held
for 4.5 min. The transfer line was held at 280 C and the detector
voltages at 1054 V. Total Ion Chromatogram (TIC)mass spectrawere
acquired at 45e550 m/z, at an acquisition frequency of 1.08 spectra
s1. The ionisation source used was electron ionization (EI) and the
energy was 70 eV. The solvent delay time of 7.5 min ensured that
the source ﬁlament was not saturated and damaged with deriva-
tization reagent. Data acquisition and spectral analysis were per-
formed using MassHunter. Qualitative identiﬁcation of the
compounds was performed according to the Metabolomics Stan-
dard Initiative (MSI) Chemical Analysis Workgroup (Sumner et al.,
2007) using standard GC-MS reference metabolite libraries of
Wiley, NIST 11 and NIST EPA/together with Kovats retention Indices
based on the referenced n-alkane retention times (C8-C40 Alkanes
Calibration Standard, Sigma-Aldrich, Australia). For peak integra-
tion, a 5 point detection, ﬁltering (default settings) was set with a
start threshold of 0.2 and a stop threshold of 0.0 for 10 scans per
sample.
Chemometric and statistical analysis was undertaken predom-
inately using SIMCA 13.0.3, a chemometric software package
(Umetrics AG, Sweden), and post-analysis Fold Change analysis
using MetaboAnalyst 2.0 (Xia et al., 2012), an online statistical
package (TMIC, Canada). Peak areas were taken into consideration
for statistical analyses. Data were normalised with respect to the
internal standards (adonitol and 13C-Sorbitol). Chromatography
peaks were considered signiﬁcant where the signal to noise (S/N)
ratio was >50, the Fold Change (FC) was >2.0, and p-values were
0.05. The calculated p-values were corrected using the Benjamini-
Hochberg (BH) adjustment method taking into account a false
discovery rate (FDR) threshold of 0.25.
The data generated by mass spectral analyses were normalized
with respect to internal standards Relative Standard Deviation
(RSD ¼ 5.14%), where a magnitude of 1 fold change (FC) referred to
the concentration of 10 mg/l. The normalised data were log trans-
formed and further analysed by Principal Component Analysis
(PCA) (Fig. S1) combined with a ‘DModX’ or ‘Distance of observa-
tion’ plot of active and control fractions (Fig. S2). The two dimen-
sional scatter plot displayed variables with respect to each other
and controls. An unsupervised statistical approach using PCA wasundertaken on the combined dataset in order to investigate any
sub-data grouping, which was not evident (see Fig. S1 and Fig. S2
for the PCA and DModX plots respectively).
To accommodate the outliers and enable differentiation and
greater predictability between the groups based on metabolic
features, a Partial Least Square-Discriminant Analysis (PLS-DA) was
employed (Karpe et al., 2015a, 2015c). PLS-DA is a supervised
method used to analyse large datasets and has the ability to assess
linear/polynomial correlation between variable matrices by
lowering the dimensions of the predictive model, enabling easy
discrimination between samples and the metabolite features that
cause the discrimination (Wold et al., 2001). The data obtained
from PLS-DA were subjected to univariate analyses methods of T-
test, fold change analysis and analysis of variance (ANOVA)
(Vranova et al., 2013) in MetaboAnalyst 2.0.2.9. Antimicrobial activity
Orally administered drugs can potentially disrupt the gut
microbiota, therefore it was important to test for antimicrobial
activity. The most effective fraction was tested against Gram posi-
tive (Bacillus cereus ATCC 11778 and Staphylococcus aureus ATCC
12600), Gram negative (Pseudomonas aeruginosa ATCC 10145 and
Salmonella entrica serovar Typhimurium ATCC 13311) bacteria for
their antimicrobial activity. Overnight cultures were prepared by
inoculating approximately 2 ml Nutrient broth (NB) (Oxoid,
Australia) with a loopful of microorganism from the slant cultures.
All bacterial cultures were incubated at 37 C overnight under
aerobic conditions. For the disk diffusion test, Brain Heart Infusion
agar (Oxoid, Australia) was used as the growth medium. The disc
diffusion technique involved the following procedure; a sterile
cotton-tipped swab was dipped into each bacterial broth and used
to inoculate BHI agar plates. The plates were dried for 2e3 min
before pre-sterilised discs (6mmdiameter) were placed on the agar
surface and 5 ml of the selected fraction were added individually
onto the discs. The seeded plates were incubated at 37 C for 24 h.
Tetracycline (30 mg) disks were used as positive controls.2.10. Cell toxicity of fraction 5
Understanding the cellular toxicity is important in drug dis-
covery and eukaryotic cell cultures are accepted as the model sys-
tem of choice to get a ﬁrst approximation of toxicity (Atterwill and
Steele, 2009). Mammary epithelial MCF10A cells were seeded in
black walled, ﬂat bottom 384 well black walled plates (Corning) at
700 cells/well using a BioTek 406 automated liquid handling
dispenser (BioTek, Vermont, USA) in a total volume of 40 ml/well.
Cells were cultured in DMEM-F12 containing 5% horse serum (Life
Technologies, Australia), 20 ng/ml human epidermal growth factor
(EGF, Life Technologies, Australia), 100 ng/ml Cholera toxin (Sigma,
Australia), 0.5 mg/ml Hydrocortisone (Sigma, Australia) and 10 mg/
ml Insulin (human; Novo Nordisk Pharmaceuticals Pty Ltd). After
24 h incubation at 37 C, 5% CO2, the growthmediumwas aspirated
and the cells were treated with Fraction 5 and controls
(media ± ethanol (1%) and the chemotherapeutic compound
doxorubicin) over an 11 point dose curve and incubated for a
further 48 h. On Day 4, cell viability was measured using the Cell-
Titer-Glo® luminescent cell viability assay (Promega, Australia).
Brieﬂy, 20 ml of CellTiter-Glo®was added to each well and mixed by
shaking for 2 min. Plates were incubated for 10 min at room tem-
perature and luminescence was read on a Cytation3 plate reader
(BioTek). Doxorubicin, starting at 3 mM concentration was used as
the positive control for cell toxicity (data not shown).
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pH can inﬂuence the stability, wettability, solubility, physical
form and particle size of drug compounds. Drug degradation often
occurs by hydrolysis that can be dependent on the pH of the me-
dium and therefore pH can signiﬁcantly alter the stability of a drug
formulation (Sigfridsson et al., 2009). The pH of fraction 5 was
changed to pH 1 by the addition of HCl (Sigma, Australia). After 1 h,
the HCl was neutralized by adding 5MNaOH (Sigma, Australia) and
the pH was adjusted to 7 (Sigma, Australia). The pH-adjusted 40%
ACN fraction was then diluted and tested on adult C. elegans using
the same screening method as described in section 2.4.3. Results
3.1. Efﬁcacy of fractions from whole plant extracts of P. fel-terrae
Lour. on C. elegans adults
We fractionated P. fel-terrae Lour. plant extract using a C-18 SPE
catridge and all fractions showed some capacity to kill the worms,
but four consecutive fractions (eluted with 25%, 40%, 55% and 70%
ACN) showed a signiﬁcant effect on C. elegans young adult survival
(Fig. 1). Of the four active fractions, the 40% ACN fraction (hereafter
mentioned as Fraction 5) demonstrated the greatest efﬁcacy, killing
85e100% of C. elegans adults. It is possible that the active com-
pound(s) from Fraction 5 may have been present in the other
fractions from slight carry over, however the compound/s with the
greatest anthelmintic activity have primarily eluted in Fraction 5.Fig. 2. The effects of fraction 5 (0.01 mg/ml) on exsheathed third-stage larvae (xL3) of
Haemonchus contortus after 48 h. Results were calculated from three biological and
technical replicates (300 worms per replicate). Negative control (NC) represents LB*3.2. Efﬁcacy of fraction 5 on xL3 H. contortus
The anthelmintic activity of Fraction 5 was evaluated on
H. contortus ex-sheathed L3 motility using the motility index assay.
We performed three technical replicates and three biological re-
peats using the same concentration as with C. elegans (0.01 mg/ml).
Fraction 5 decreased the motility of H. contortus xL3 by almost 50%
compared to the negative control (Fig. 2). This suggests the pres-
ence of concentrated active compound/s with anthelmintic activity
in Fraction 5.Fig. 1. The effects of fractions (0.01 mg/ml) of Picria fel-terrae Lour. plant extracts on young
technical replicates (10 worms per well per replicate). Error bar indicates the standard erro
positive control 1 (PC1) represent doramectin (0.1 mg/ml) containing 1% ethanol and po
**P  0.01; ***P  0.001.3.3. Metabolic proﬁling of fraction 5
Untargeted GC-MS analysis of Fraction 5 (active fraction) and
Fraction 2 were tested for the identiﬁcation of any putative anti-
nematodal components. This approach was able to identify ca.158
metabolites from both fractions. Fraction 2, the comparatively
inactive fraction of the two, was used as the negative control for
comparison against Fraction 5. Application of PLS-DA increased the
linearity and the overall model predictability (Fig. 3A). The analysis
was able to improve the metabolite behavioural distribution, as
evident from a distinct metabolite distribution (Fig. 3 B). Overall, of
158 metabolites identiﬁed by GC-MS, 132 statistically signiﬁcant
metabolites were common to both fractions (Fig. 4) Themetabolites
present in fraction 5 were differentiated from fraction 2 by the
distribution of their fold change (FC) values (Table 1). The 50 most
signiﬁcant metabolites identiﬁed are provided in Table S1.
Medium chained fatty acids (MCFAs) were the highest repre-
sented species identiﬁed in fraction 5, and included heptadecanoic
acid (FC ¼ 283.2), 2, 3-bis [TMS]oxy) butanedioic acid (FC ¼ 66.1)
and docosanoic acid (FC ¼ 45.9). Benzoic acid, 4-[(trimethylsilyl)
oxy]-, trimethylsilyl ester or 4-hydroxy benzoic acid was also highly
represented in this fractionwith a FC value of 51.131, equivalent to a
concentration of ~511.3 mg/l. This compound has been identiﬁed
from various higher plants as a secondary metabolic constituentadult Caenorhabditis elegans after 72 h. Results were calculated from 3 biological and
r of the mean (SEM). Negative control (NC) represents M9 containing 1% ethanol and
sitive control 2 represent levamisole (0.1 mg/ml) containing 1% ethanol. *P  0.05;
containing 1% ethanol. Error bar indicates the standard error of the mean (SEM).
Fig. 3. Geometric proﬁles of active (Fraction 5) and control (Fraction 2) fractions. (A)
PLS- DA score scatter plot, where each point on the scatter plot refers to a single
sample, with R2X (cumulative) ¼ 84.3%, R2Y (cumulative) ¼ 99.9% and Q2
(cumulative) ¼ 98.2%; and (B) PLS- DA loading scatter plot where the yellow ﬁve
pointed star labels denote the fraction distribution, while the circles represent all the
metabolites under consideration and their orientation. (For interpretation of the ref-
erences to colour in this ﬁgure legend, the reader is referred to the web version of this
article.)
Fig. 4. Volcano plot displaying the differential expressing metabolites in active and control
and t-tests threshold (y) 0.05. The signiﬁcant metabolites expressed in Fraction 5 (black circl
points on the plot (white circles) were considered as statistically non-signiﬁcant.
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3,4-bis(trimethylsiloxy)cinnamate) was also observed at consider-
able levels in Fraction 5 (FC ¼ 35.136 or 351.4 mg/l). We expect
there are other biologically active metabolites in this fraction that
were not identiﬁed asmajor constituents in the GC-MS analysis due
to detection limits of the system and current mass spectral
databases.
3.4. Antimicrobial activity of PE1 fraction 5
Puriﬁed compounds previously identiﬁed from P. fel-terrae plant
extracts have shown antimicrobial activity (Huang et al., 1999; Zou
et al., 2006). Therefore, we tested Fraction 5 against two Gram
positive (B. cereus and S. aureus) and two Gram negative
(P. aeruginosa and S. enterica) bacteria using the disk diffusion test
on Brain Heart Infusion agar. Tetracycline (30 mg) disks were used as
positive controls. Interestingly, Fraction 5 did not inhibit growth of
any of the tested bacterial strains while as expected tetracycline
inhibited the growth of all four bacteria (data not shown), con-
ﬁrming the validity of the test (Galappathie et al., 2014). This in-
dicates that the anthelmintic activity of the compounds in Fraction
5 is highly speciﬁc and is not exhibiting general toxicity.
3.5. Mammalian cell toxicity
We used the immortalized humanmammary epithelial cell line,
MCF10A, to examine the potential toxicity of Fraction 5. Fraction 5
demonstrated minimal and statistically insigniﬁcant cytotoxicity at
concentrations less than 0.015 mg/ml compared to the negative
control (non-treated) (Fig. 5). Levamisole did not show statistically
signiﬁcant cytotoxic activity below 0.5 mg/ml. Since Fraction 5 was
used at 0.01 mg/ml for anthelmintic activity testing against both
C. elegans and H. contortus, it could be concluded that there was
minimal toxicity at this concentration.
3.6. pH stability of fraction 5
We evaluated the pH stability of Fraction 5 at seven different pHfractions. Important features selected by volcano plot with fold change threshold (x) 2
es) and Fraction 2 (grey circles) was taken into consideration for further analyses. Other
Table 1
Top 20 metabolites characterised by fold change as analysed and identiﬁed by GC-MS and univariate and multivariate statistical analyses. Note: The ﬁrst 14 rows represent
metabolites with highest FC values in Fraction 5, while Rows 15e20 represent metabolites with highest FC values in Fraction 2. *Represents the corrected P value using the
Benjamini-Hochberg (BH) adjustment taking into account the false discovery rate (FDR) threshold of 0.25. A detailed table is presented in supplementary materials (Table S1).
Metabolites Kovats retention index Fold change P value Corrected P value*
Fraction 5
Pentadecanoic acid, n- (1TMS) 1970.853 5078.6 0.0027 0.0049
Glyceric acid, L- (3TMS) 1362.987 4535.5 0.0362 0.0517
1,3-bis(trimethylsilyl)-1,3-diaza-2-germa(II)indane 1980.155 4021.0 0.0268 0.0440
Phosphoric acid (3TMS) 1309.482 3365.1 0.2031 0.2471
Glucopyranoside-6,6-d2, methyl-tetrakis-o-(trimethylsilyl)- 3268.133 1508.4 0.0026 0.0049
Compound 215 2728.253 1083.6 0.0001 0.0003
Compound 220 2728.857 1083.6 0.0001 0.0003
Hexakistrimethylsilyl allitol-3-d1 ether 1908.271 894.9 0.2341 0.2472
Glucose, D- (1MEOX) (5TMS) 1914.547 807.6 0.1098 0.1464
Butane, 1,2,3-tris(trimethylsiloxy)- 1325.525 716.4 0.0005 0.0011
Methyl-a-D-Glucopyranoside (4TMS) 2999.641 542.2 0.0000 0.0003
Fructose, D- (1MEOX) (5TMS) 1889.568 531.5 0.2345 0.2472
Urea (2TMS) 1296.785 527.7 0.0286 0.0440
Gluconic acid-1,5-lactone, D- (4TMS) 1915.996 524.3 0.2348 0.2472
Fraction 2
Lactic acid, DL- (2TMS) 1070.708 0.7904 0.8200 0.8200
Unknown 1 1725.077 0.4721 1.26e08 6.3e08
25-Hydroxycholecalciferol 1802.400 0.1597 6.16e10 6.16e09
D-Tartaric acid (dTMS) 1774.810 0.1182 1.72e09 1.15e08
Sophorose (dTMS) 1687.649 0.1172 3.97e07 1.59e06
Xylitol (5TMS) 1746.566 0.0735 5.09e17 1.02e15
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described above. After 72 h, all treated fractions demonstrated
statistically similar efﬁcacy compared to the untreated Fraction 5
(Fig. 6), indicating that the active compoundswith Fraction 5 are pH
stable.
4. Discussion
This study demonstrated that Fraction 5 of P. fel-terrae Lour.
plant extracts has signiﬁcant impacts on mortality and motility of
C. elegans and H. contortus, respectively. Moreover, Fraction 5 con-
tains biologically active constituents that were pH stable and
showed mimimal cytotoxicity in mammalian cells at the thera-
peutic concentration used. The GC-MS analysis of Fraction 5 iden-
tiﬁed a complex mixture of compounds. Although we report the 50
most abundant compounds identiﬁed, we recognise the possibility
that there may be other potent compounds with good anthelminticFig. 5. Analysis of cytotoxicity of Fraction 5. Results were calculated from two biologicalactivities present at lower concentrations but undetectable in our
system.
While the biologically active compounds were eluted in Fraction
5, there were other potential bioactive compound/s present in
Fractions 4, 6 and 7, although they showed considerably less
anthelmintic activity. Of the 158 metabolites identiﬁed in Fraction
5, 132 were common to the inactive Fraction 2, leaving 26 speciﬁc
and highly concentrated molecules that could relate to the effects
observed in Fraction 5. It remains unclear what the nature of the
anthelmintic activity is in Fraction 5. Further chemical dissection of
this fraction will help determine whether a single compound or
combination of compounds associatewith the anthelmintic activity
identiﬁed here. Additionally, a limitation of single quadrupole GC-
MS based metabolomics is the need to derivatise samples prior to
analysis and the difﬁculty in identifying and characterizing some
plant based secondary and tertiary metabolites. As such, any future
work analysing compounds that are associated with theand 4 technical replicates. Error bar indicates the standard error of the mean (SEM).
Fig. 6. Effects of pH-treated Fraction 5 (0.01 mg/ml) of Picria fel-terrae Lour. plant
extracts on young adult Caenorhabditis elegans after 72 h. Results were calculated from
three biological and technical replicates (10 worms per well per replicate). Error bar
indicate the standard error of the mean (SEM). Negative control (NC) represents M9
containing 1% ethanol.
R. Kumarasingha et al. / International Journal for Parasitology: Drugs and Drug Resistance 6 (2016) 171e178 177anthelmintic activity of P. Fel-terrae Lour. plant extracts would need
to consider a suite of complementary techniques (i.e., liquid chro-
matography (LC), e.g., LC-ToFMS (time of light mass spectrometry),
LC  LC-ToFMS and LC-HRT (high resolution time of ﬂight mass
spectrometry) and more advanced GC techniques (e.g., GC-ToFMS,
GC  GC-ToFMS and GC-HRT). This will likely lead to the discov-
ery and identiﬁcation of key biomarkers within isolated fractions
through the comprehensive metabolomics mapping of P. Fel-terrae
Lour. plant extracts.
MCFAswere abundant in Fraction 5, and this class of compounds
(such as hexanoic, and decanoic acids at 5 mg/L concentrations)
have been found to inhibit growth and resultant fermentation
(Edwards et al., 1990; Legras et al., 2010). Recently, it has been
shown that high concentrations of MCFAs, such as hexadecanoate
(palmitic acid) and dodecanoate, caused growth inhibition of
Aspergillus niger (Karpe et al., 2015b). Furthermore, some MCFAs
such as palmitic, oleic, myristic and capric acids have been effective
in inhibiting egg hatching by up to 84%, and causing 50% juvenile
mortality in root knot nematodes, including Meloidogyne incognita
(see Zhang et al., 2012) and M. halpa (see Sharma et al., 2014).
The metabolite 4-hydroxybenzoic acid is either related to or is a
member of the ecathechins family and has been reported to show
biological activity (Faizi et al., 2011); 4-hydroxybenzozic acid
identiﬁed from the ﬂoral parts of Tagetes patula L has been shown in
an in vitro toxicity bioassay to possess anti-nematodal activity (40%
mortality at 5 ng/ml) against the free living larvae of the plant cyst
nematode Heterodera zeae (see Faizi et al., 2011). Likewise, nema-
ticidal and paralysis activities of 4-hydroxybenzoic acid analogues,
isolated from chinaberry (Melia azedarach L.), have been reported
against free living larvae of the plant root-knot nematode Meloi-
dogyne incognita (EC50/48h 871 mg/ml) (Aoudia et al., 2012).
Hydroxycinnamic acids are secondary metabolites and antioxi-
dants (Olthof et al., 2001), and are an intermediate of lignin
biosynthesis in higher plants (Boerjan et al., 2003). Hydroxycin-
namic acids have been shown to possess anti-nematodal effects
against free living larvae M. incognita when isolated from china-
berry (Melia azedarach) (EC50 > 1000 mg/ml) (see Aoudia et al.,
2012) and the plant pathogenic nematode Pratylenchus scribneri
when isolated from Lolium arundinaceum (see Bacetty et al., 2009).
Plant-derived compounds have been shown to have clear efﬁ-
cacy and safety and have been used to develop semi-synthetic or
synthetic drugs (Tagboto and Townson, 2001). This studydemonstrates that Fraction 5 possesses anthelmintic activity
against both free living C. elegans and parasitic H. contortus. Further
analyses should be conducted to understand the mechanism of
anthelmintic activity of the active compound/s within Fraction 5.
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